-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
How Much Of CSPC Pharmaceutical Group Limited (HKG:1093) Do Insiders Own?
How Much Of CSPC Pharmaceutical Group Limited (HKG:1093) Do Insiders Own?
Every investor in CSPC Pharmaceutical Group Limited (HKG:1093) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don't tell me what you think, tell me what you have in your portfolio.
CSPC Pharmaceutical Group is a pretty big company. It has a market capitalization of HK$102b. Normally institutions would own a significant portion of a company this size. In the chart below, we can see that institutions are noticeable on the share registry. Let's delve deeper into each type of owner, to discover more about CSPC Pharmaceutical Group.
See our latest analysis for CSPC Pharmaceutical Group
SEHK:1093 Ownership Breakdown August 8th 2022What Does The Institutional Ownership Tell Us About CSPC Pharmaceutical Group?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
CSPC Pharmaceutical Group already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of CSPC Pharmaceutical Group, (below). Of course, keep in mind that there are other factors to consider, too.
SEHK:1093 Earnings and Revenue Growth August 8th 2022Hedge funds don't have many shares in CSPC Pharmaceutical Group. Our data suggests that Dongchen Cai, who is also the company's Top Key Executive, holds the most number of shares at 23%. When an insider holds a sizeable amount of a company's stock, investors consider it as a positive sign because it suggests that insiders are willing to have their wealth tied up in the future of the company. With 7.3% and 6.1% of the shares outstanding respectively, UBS Asset Management and Common Success International Limited are the second and third largest shareholders.
We did some more digging and found that 8 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
Insider Ownership Of CSPC Pharmaceutical Group
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our information suggests that insiders maintain a significant holding in CSPC Pharmaceutical Group Limited. It has a market capitalization of just HK$102b, and insiders have HK$24b worth of shares in their own names. That's quite significant. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.
General Public Ownership
The general public, who are usually individual investors, hold a 37% stake in CSPC Pharmaceutical Group. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Private Company Ownership
We can see that Private Companies own 6.3%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand CSPC Pharmaceutical Group better, we need to consider many other factors.
I always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph.
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
石藥集團集團有限公司(HKG:1093)的每一位投資者都應該知道最強大的股東羣體。大公司通常有機構作為股東,我們通常會看到內部人士持有小公司的股份。我通常喜歡看到一定程度的內部人持股,即使只是一小部分。正如納西姆·尼古拉斯·塔勒布所説,不要告訴我你的想法,告訴我你的投資組合中有什麼。
石藥集團集團是一家相當大的公司。其市值為1020億港元。通常情況下,機構會持有如此規模的公司的很大一部分股份。在下面的圖表中,我們可以看到,機構在股票登記處是顯而易見的。讓我們更深入地挖掘每一種類型的所有者,以更多地瞭解石藥集團集團。
查看我們對石藥集團集團的最新分析
聯交所:1093所有權分類2022年8月8日關於石藥集團集團,機構持股告訴了我們什麼?
機構投資者通常將自己的回報與經常跟蹤的指數的回報進行比較。因此,他們通常確實會考慮收購被納入相關基準指數的較大公司。
石藥集團集團已有登記在冊的機構。事實上,他們在該公司擁有可觀的股份。這意味着為這些機構工作的分析師已經看過了這隻股票,他們喜歡它。但就像其他人一樣,他們也可能錯了。如果兩個大型機構投資者試圖同時拋售一隻股票,股價大幅下跌的情況並不少見。因此,值得查看石藥集團集團過去的盈利軌跡(見下圖)。當然,請記住,還有其他因素需要考慮。
聯交所:1093盈利及收入增長2022年8月8日對衝基金在石藥集團集團持有的股份並不多。我們的數據顯示,同時也是該公司首席執行官的蔡東晨持有的股份最多,為23%。當一名內部人士持有一家公司相當數量的股票時,投資者認為這是一個積極的跡象,因為這表明內部人士願意將他們的財富與公司的未來掛鈎。瑞銀資產管理和共同成功國際有限公司分別持有7.3%和6.1%的流通股,是第二和第三大股東。
我們做了更多的挖掘,發現大股東中有8個約佔登記的51%,這意味着除了大股東之外,還有一些小股東,從而在一定程度上平衡了彼此的利益。
研究機構持股是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒,也可以達到同樣的效果。相當多的分析師追蹤這隻股票,所以你可以很容易地研究預測增長。
石藥集團集團的內部人持股
公司內部人的定義可能是主觀的,而且在不同的司法管轄區之間確實有所不同。我們的數據反映了個別內部人士,至少捕捉到了董事會成員。管理層最終要向董事會負責。然而,經理人擔任執行董事會成員並不少見,尤其是如果他們是創始人或首席執行官的話。
大多數人認為內部人持股是積極的,因為它可以表明董事會與其他股東很好地結盟。然而,在某些情況下,太多的權力集中在這個羣體中。
我們的信息顯示,內部人士持有石藥集團集團有限公司的大量股份。它的市值只有102B港元,內部人士以自己的名義持有價值240億港元的股票。這是非常重要的。很高興看到這樣的投資水平。你可以在這裏查看這些內部人士最近是否一直在買入。
一般公有制
通常為個人投資者的普通公眾持有石藥集團集團37%的股份。這種規模的所有權雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。
私營公司所有權
我們可以看到,私營公司擁有6.3%的已發行股份。僅從這一事實很難得出任何結論,因此值得調查一下誰擁有這些私營公司。有時,內部人士或其他關聯方通過一家獨立的私人公司擁有上市公司的股份。
接下來的步驟:
擁有一家公司股票的不同集團總是值得考慮的。但要更好地理解石藥集團集團,我們還需要考慮許多其他因素。
我總是喜歡找一個收入增長的歷史。你也可以,通過訪問這張免費的歷史收入和收益圖表詳細圖表.
但最終這就是未來,而不是過去,這將決定這家企業的所有者將做得多好。因此,我們認為,看看這份免費報告是明智的,它顯示了分析師是否預測到了更光明的未來。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧